BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

VANCOUVER, British Columbia, April 03, 2024 -- BetterLife Pharma Inc. , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental...

Related Keywords

United Kingdom ,Vancouver ,British Columbia ,Canada ,British ,Ahmad Doroudian ,David Melles ,Steven Sangha ,Betterlife Pharma ,Betterlife Pharma Inc ,Qlife Pharma ,Convertible Debentures ,Chief Executive Officer ,Multilateral Instrument ,Investor Relations ,Markets ,